查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1466036

心血管药物市场：按药物类型、适应症、给药途径、购买型态和最终用户划分 - 全球预测 2024-2030

Cardiovascular Drugs Market by Drug Type, Disease Indication, Route of Administration, Mode of Purchase, End-Users - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年心血管药物市场规模为826.5亿美元，预计2024年将达901.3亿美元，2030年将达1526.1亿美元，复合年增长率为9.15%。

心血管药物包括用于治疗心臟病和相关循环系统疾病的各种药物。这包括各种治疗药物类别，例如抗高血压药、抗凝血药、抗心律不整药、抗心绞痛药和降胆固醇药。这些药物主要用于高血压、高血脂症、冠状动脉疾病、心律不整和心臟衰竭等疾病的临床治疗。全球心血管疾病盛行率不断上升，特别是人口老化，导致对心血管药物的需求不断增加。新兴国家医疗保健支出的增加和医疗基础设施的改善正在推动市场扩张，对副作用和安全性的担忧可能导致产品召回、品牌形像下降并影响市场成长。个人化医疗和生技药品的新进展正在为心血管药物市场创造重大机会。此外，不断增加的引入新型心血管的研发活动预计将推动市场成长。

主要市场统计
基准年[2023] 826.5亿美元
预测年份 [2024] 901.3亿美元
预测年份 [2030] 1526.1亿美元
复合年增长率（%） 9.15%

药物类型使用血管收缩素素抑制剂治疗肾臟疾病的需求不断增加

血管收缩素抑制剂是一类用于治疗高血压、心臟衰竭和某些肾臟疾病等疾病的药物。这些药物透过阻断血管收缩素（一种使血管变窄的化学物质）的作用来发挥作用。血管收缩素抑制剂主要有两种类型：血管收缩素转化酵素（ACE）抑制剂和血管收缩素II受体阻断剂（ARB）。抗凝血剂通常被称为血液稀释剂。防止新的血栓形成并阻止现有的血栓变大。这类药物对于心房颤动、深层静脉栓塞症、肺动脉栓塞和某些类型手术的患者至关重要。高血脂症药物用于降低血液中的脂质水平，特别是胆固醇。它是预防和治疗动脉硬化和冠状动脉疾病的基本药物。他汀类药物是此类药物中最常见的药物。抗高血压药物用于控制高血压（高血压）。在这一广泛的药物类别中，有多种药物类别，包括β阻断剂、利尿剂和钙通道阻断剂，每种药物都有不同的机制。抗血小板药物透过抑制血小板聚集来防止动脉血栓的形成。这对于有心肌梗塞、不稳定心绞痛病史的患者以及曾放置支架或冠状动脉绕道手术术的患者尤其重要。

适应症：增加心血管疾病在高血压管理的使用频率

心律不整是心律不整，可导致多种併发症，包括中风和心臟衰竭。用于治疗心律不整的药物包括抗心律不整药物、 β阻断剂和钙通道阻断剂。该领域常用的处方药，如Amiodarone、索他洛尔和地高辛，都符合控制和维持正常心律的需要。冠状动脉疾病 (CAD) 是一种斑块在冠状动脉中积聚的疾病，通常采用降胆固醇药物、硝酸盐、 β阻断剂和抗血小板药物联合治疗。他汀类药物是 CAD 药物治疗的基石，旨在降低随后心臟病发作和其他心血管事件的风险。高血脂症的特征是血液中脂质含量升高，是心血管疾病的重要危险因子。治疗方法包括他汀类药物、原纤维酸衍生物、胆汁酸分泌抑制剂和胆固醇吸收抑制剂。治疗的目标是降低低密度脂蛋白胆固醇并降低心血管风险。多种药物用于治疗高血压，包括利尿剂、ACE 抑制剂、血管收缩素II 受体阻断剂 (ARB)、 β阻断剂和钙通道阻断剂。这些药物有助于控制血压并降低心臟病、中风和肾臟疾病的风险。

型态购买：越来越多的心血管成药可以在柜檯购买，用于治疗与心臟健康相关的轻微症状。

非处方心血管药物是无需处方笺即可购买的药物。当按照指示用于与心血管健康相关的轻微健康问题时，通常被认为是安全有效的。消费者正在使用成药来控制与心臟健康相关的轻微症状，例如使用稀释血液的阿斯匹灵来预防心臟病发作，或使用大蒜锭剂来控制轻度高血压。成药的便利性、可用性和可负担性使其成为自我治疗和主动健康管理的热门选择。处方笺心血管药物旨在治疗更严重的疾病，必须得到医疗保健专业人员的批准。这些药物具有很高的副作用潜力，通常需要医疗监测。当患者患有严重的心血管疾病且无法用非处方药治疗时，就会出现处方笺药的需求。

最终用户：医院药房扩大心血管药物用于急性疾病治疗的采用

医院药房是满足住院和门诊病人需求的心血管药物配药的重要管道。这些设施主要负责直接管理患者，包括接受手术和急性病症治疗的患者。在这里，综合循环系统药物是根据需要首选的，并且 24/7 随时可用，用于紧急情况和持续的患者治疗。线上药局的兴起彻底改变了患者获取药物（包括心血管药物）的方式。这里基于需求的主要偏好是便利性、可及性以及通常具有竞争力的价格。患有需要持续药物治疗的慢性病患者（例如高血压或心臟衰竭）可能会发现订阅服务特别有吸引力。零售药局是一般民众（尤其是心臟病较不严重的人）取得心血管药物的重要网路基地台。这里的偏好是因为药品的现成性、与药剂师的个人咨询以及相关健康监测服务的提供。

区域洞察

由于高额医疗支出、先进的医疗基础设施以及大量的研发活动，美洲在全球心血管药物市场中保持重要地位。在重视功效和品牌声誉的消费群的推动下，美国市场对创新品牌药品表现出强劲的需求。欧盟国家老化率高，心血管药物需求强劲。欧盟的市场动态是由严格的法规和大量的全球製药公司存在所决定的。各种医疗保健系统的成本控制措施导致了品牌药和学名药的混合使用。在中东和非洲，随着心臟病发病率的增加，心血管药物市场正在发展。由于人口老化和心血管疾病（CVD）盛行率的增加，亚太地区正迅速成为心血管药物的重要市场。中国和印度是该地区的重要国家，因为两国人口众多且CVD发病率迅速上升。由于全部区域经济阶层的多样性，在消费者需求中，负担得起的医疗保健和获得学名药至关重要。

FPNV定位矩阵

FPNV 定位矩阵对于评估心血管治疗市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对心血管药物市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告在以下方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4.竞争评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.心血管药物市场规模及预测如何？

2.心血管药物市场预测期内需要考虑投资的产品、细分市场、应用和领域有哪些？

3.心血管药物市场的技术趋势和法规结构是什么？

4.心血管治疗市场主要厂商的市场占有率为何？

5.进入心血管药物市场合适的型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 心血管疾病盛行率上升
      • 加大药物研发研发投入
      • 政府在心血管疾病预防与控制的倡议
    • 抑制因素
      • 产品召回与心血管药物的高成本
    • 机会
      • 心血管药物优惠报销政策和项目
      • 治疗心血管疾病新药介绍
    • 任务
      • 高效、安全药物开发的复杂性
  • 市场区隔分析
    • 药物类型：越来越需要血管收缩素抑制剂来治疗某些类型的肾臟疾病
    • 疾病适应症：越来越多地使用心血管疾病来治疗高血压
    • 如何购买：越来越多地使用成药心血管药物来控制与心臟健康相关的轻微症状
    • 最终用户：医院药局越来越多地采用心血管药物来治疗急性疾病
  • 市场趋势分析
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法规结构分析

第六章按药物类型分類的心血管治疗药物市场

  • 血管收缩素抑制剂
  • 抗凝血物
  • 高血脂症
  • 降血压
  • 抗血小板药物

第七章心血管药物市场：依疾病适应症

  • 心律不整
  • 冠状动脉疾病
  • 高血脂症
  • 高血压

第八章心血管药物市场：依给药途径

  • 静脉
  • 口服
  • 皮下的

第九章 心血管药物市场依采购方式划分

  • 成药
  • 处方药

第10章心血管药物市场：依最终用户分类

  • 医院药房
  • 网路药房
  • 零售药房

第十一章美洲心血管药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太地区心血管药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲心血管药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争场景分析
    • 百时美施贵宝投资 1 亿美元治疗心血管疾病的 RNA 药物
    • 美国FDA核准Lexicon Pharma 的心臟衰竭治疗药物
    • Glenmark Pharmaceuticals 在印度推出心臟衰竭治疗药物

第15章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-434CCDA05198

[184 Pages Report] The Cardiovascular Drugs Market size was estimated at USD 82.65 billion in 2023 and expected to reach USD 90.13 billion in 2024, at a CAGR 9.15% to reach USD 152.61 billion by 2030.

Cardiovascular drugs encompass the range of medications prescribed for the treatment of heart diseases and related circulatory problems. This includes a variety of therapeutic drug classes, such as antihypertensives, anticoagulants, antiarrhythmics, antianginals, and cholesterol-lowering drugs. These medications are primarily used in the clinical management of conditions such as hypertension, hyperlipidemia, coronary artery disease, arrhythmias, and heart failure. The increasing incidence of cardiovascular conditions globally, especially among the aging population, is expanding the need for cardiovascular drugs. Rising healthcare spending and improvements in healthcare infrastructure in emerging economies are propelling market expansion. Adverse drug reactions and safety concerns lead to product recalls and tarnish the brand image, subsequently impacting the market growth. New advances in personalized medicine and biologics are presenting significant opportunities in the cardiovascular drug market. Additionally, rising research & development activities to introduce novel cardiovascular are expected to fuel the market growth.

KEY MARKET STATISTICS
Base Year [2023] USD 82.65 billion
Estimated Year [2024] USD 90.13 billion
Forecast Year [2030] USD 152.61 billion
CAGR (%) 9.15%

Drug Type: Increasing need for angiotensin inhibitors to treat certain types of kidney diseases

Angiotensin inhibitors are a class of drugs used to treat conditions such as high blood pressure, heart failure, and certain types of kidney disease. These medications work by blocking the effects of angiotensin, a chemical that narrows blood vessels. The two main types of angiotensin inhibitors are Angiotensin-Converting Enzyme (ACE) inhibitors and Angiotensin II Receptor Blockers (ARBs). Anticoagulants are often referred to as blood thinners. They prevent the formation of new blood clots and stop existing clots from getting larger. This drug type is pivotal for patients with atrial fibrillation, deep vein thrombosis, pulmonary embolism, or those who have undergone certain types of surgeries. Antihyperlipidemic drugs are used to lower lipid levels in the blood, especially cholesterol. They are critical for the prevention and management of atherosclerosis and coronary artery disease. Statins are the most common class within this category. Antihypertensive drugs are used to manage hypertension (high blood pressure). This broad drug category includes a variety of medication classes, such as beta-blockers, diuretics, calcium channel blockers, etc., each with different mechanisms of action. Antiplatelet drugs inhibit platelet aggregation to prevent arterial thrombus formation. They are especially important for patients with a history of myocardial infarction, unstable angina, and those who have had stents placed or undergone coronary artery bypass graft surgery.

Disease Indication: Rising usage of cardiovascular diseases for the management of hypertension

Arrhythmias are irregular heartbeats that can lead to various complications, including stroke and heart failure. Drugs used to treat arrhythmia include antiarrhythmic agents, beta-blockers, and calcium channel blockers. Commonly prescribed medications in this segment, such as amiodarone, sotalol, and digoxin, are aligned with the need to control and maintain normal heart rhythm. Coronary artery disease (CAD), a condition marked by the buildup of plaque in the coronary arteries, is commonly managed with a combination of cholesterol-lowering drugs, nitrates, beta-blockers, and antiplatelet agents. Statins are the foundation of pharmacotherapy for CAD, aimed at reducing the risk of subsequent heart attacks and other cardiovascular events. Hyperlipidaemia, characterized by elevated levels of lipids in the blood, is a key risk factor for cardiovascular disease. The therapeutic approach includes statins, fibric acid derivatives, bile acid sequestrants, and cholesterol absorption inhibitors. The goal of treatment is to lower LDL cholesterol and thereby reduce cardiovascular risk. Hypertension, or high blood pressure, is treated with several classes of drugs, including diuretics, ACE inhibitors, angiotensin II receptor blockers (ARBs), beta-blockers, and calcium channel blockers. These medications help manage blood pressure and reduce the risk of heart attack, stroke, and kidney disease.

Mode of Purchase: Rising usage of over-the-counter cardiovascular drugs for managing minor symptoms associated with heart health

Over-the-counter cardiovascular drugs are medications that can be purchased without a prescription. They are generally considered safe and effective when used as directed for minor health concerns related to cardiovascular health. Consumers tend to prefer OTC drugs for managing minor symptoms associated with heart health, such as using aspirin for its blood-thinning properties to prevent heart attacks or controlling mild hypertension with garlic pills. The convenience, accessibility, and affordability of OTC drugs make them a popular choice for self-medication and proactive health care management. Prescription-based cardiovascular drugs are designed to treat more severe conditions and require a healthcare provider's authorization for use. These medications often have a more significant potential for side effects and necessitate medical oversight. The need for prescription-based drugs arises when patients experience serious cardiovascular illnesses that cannot be managed with OTC medication.

End-Users: Growing adoption of cardiovascular drugs by hospitals pharmacies for the treatment of acute conditions

Hospital pharmacies represent a critical channel for the dispensation of cardiovascular drugs tailored to inpatient and outpatient needs. These facilities primarily deal with direct patient administration, including patients undergoing surgery or treatment for acute conditions. The need-based preference here is for a comprehensive range of cardiovascular medications readily available on a 24/7 basis to cater to emergency situations and ongoing patient regimens. The rise of online pharmacies has revolutionized how patients obtain their medications, cardiovascular drugs included. The primary need-based preference here is convenience, accessibility, and often competitive pricing. Patients with chronic conditions requiring ongoing medication, such as hypertension or heart failure, may find subscription services particularly appealing. Retail pharmacies serve as a vital access point for cardiovascular drugs to the general public, especially for those with less acute forms of heart disease. The preference here stems from the immediate availability of medication, personal interaction with pharmacists for consultation, and the provision of associated health monitoring services.

Regional Insights

The Americas maintain a significant position in the global cardiovascular drugs market because of high healthcare expenditure, sophisticated healthcare infrastructure, and significant research and development activities. The U.S. market exhibits strong demand for innovative and branded drugs bolstered by a consumer base that prioritizes efficacy and brand reputation. The European Union (EU) countries exhibit a strong demand for cardiovascular drugs with a large aging population. Market dynamics in the EU are shaped by rigorous regulations and the presence of numerous global pharmaceutical players. There is a mix of preference for brand-name drugs and generics driven by cost-containment measures within various healthcare systems. In the Middle East and Africa, the market for cardiovascular drugs is evolving with rising incidence rates of heart diseases. The Asia Pacific region is rapidly emerging as a significant market for cardiovascular drugs, driven by a growing aging population and an increasing prevalence of cardiovascular diseases (CVDs). In this region, China and India are significant countries due to their large populations and the burgeoning incidence of CVDs. In terms of consumer needs, access to affordable healthcare and generic medicine is paramount due to diverse economic strata across the region.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Cardiovascular Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cardiovascular Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Cardiovascular Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Apotex Inc., AstraZeneca PLC, Auro Pharma Inc., Bausch Health Companies Inc., Baxter International Inc., Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Chiesi USA, Inc., Cipla Limited, Cornerstone Therapeutics Inc., CYTOKINETICS, Incorporated, Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Ferring B.V., Gilead Sciences, Inc., Johnson & Johnson Services, Inc., Merck KGaA, Novartis AG, Novo Nordisk A/S, Otsuka Holdings Co., Ltd., Par Pharmaceutical by Endo International, Pfizer Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., WellSpring Pharmaceutical Corporation, and Zydus Group.

Market Segmentation & Coverage

This research report categorizes the Cardiovascular Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Type
    • Angiotensin Inhibitors
    • Anticoagulants
    • Antihyperlipidemic
    • Antihypertensive
    • Antiplatelet Drugs
  • Disease Indication
    • Arrhythmia
    • Coronary Artery Disease
    • Hyperlipidaemia
    • Hypertension
  • Route of Administration
    • Intravenous
    • Oral
    • Subcutaneous
  • Mode of Purchase
    • Over-The-Counter Drugs
    • Prescription-Based Drugs
  • End-Users
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Cardiovascular Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cardiovascular Drugs Market?

3. What are the technology trends and regulatory frameworks in the Cardiovascular Drugs Market?

4. What is the market share of the leading vendors in the Cardiovascular Drugs Market?

5. Which modes and strategic moves are suitable for entering the Cardiovascular Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising Prevalence of Cardiovascular Disorders
      • 5.1.1.2. Increasing R&D Investments for Drug Development
      • 5.1.1.3. Government Initiatives for Prevention & Control of Cardiovascular Diseases
    • 5.1.2. Restraints
      • 5.1.2.1. Product Recalls and High Cost of Cardiovascular Drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Favorable Reimbursement Policies and Programs for Cardiovascular Drugs
      • 5.1.3.2. Introduction of Novel Drugs for Treatment of Cardiovascular Diseases
    • 5.1.4. Challenges
      • 5.1.4.1. Complexities in Efficient and Safe Drug Development
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Type: Increasing need for angiotensin inhibitors to treat certain types of kidney diseases
    • 5.2.2. Disease Indication: Rising usage of cardiovascular diseases for the management of hypertension
    • 5.2.3. Mode of Purchase: Rising usage of over-the-counter cardiovascular drugs for managing minor symptoms associated with heart health
    • 5.2.4. End-Users: Growing adoption of cardiovascular drugs by hospitals pharmacies for the treatment of acute conditions
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework Analysis

6. Cardiovascular Drugs Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Angiotensin Inhibitors
  • 6.3. Anticoagulants
  • 6.4. Antihyperlipidemic
  • 6.5. Antihypertensive
  • 6.6. Antiplatelet Drugs

7. Cardiovascular Drugs Market, by Disease Indication

  • 7.1. Introduction
  • 7.2. Arrhythmia
  • 7.3. Coronary Artery Disease
  • 7.4. Hyperlipidaemia
  • 7.5. Hypertension

8. Cardiovascular Drugs Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intravenous
  • 8.3. Oral
  • 8.4. Subcutaneous

9. Cardiovascular Drugs Market, by Mode of Purchase

  • 9.1. Introduction
  • 9.2. Over-The-Counter Drugs
  • 9.3. Prescription-Based Drugs

10. Cardiovascular Drugs Market, by End-Users

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies

11. Americas Cardiovascular Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Cardiovascular Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Cardiovascular Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Bristol Myers pours USD 100 million into RNA drugs for cardiovascular diseases
    • 14.3.2. U.S. FDA Approves Lexicon Pharma's Drug for Heart Failure
    • 14.3.3. Glenmark Pharmaceuticals Launches Drug to Treat Heart Failure in India

15. Competitive Portfolio

  • 15.1. Key Company Profiles
  • 15.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. CARDIOVASCULAR DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. CARDIOVASCULAR DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. CARDIOVASCULAR DRUGS MARKET DYNAMICS
  • FIGURE 7. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 16. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. CARDIOVASCULAR DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 26. CARDIOVASCULAR DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CARDIOVASCULAR DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ANGIOTENSIN INHIBITORS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ANGIOTENSIN INHIBITORS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTICOAGULANTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTICOAGULANTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTIHYPERLIPIDEMIC, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTIHYPERLIPIDEMIC, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTIHYPERTENSIVE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTIHYPERTENSIVE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTIPLATELET DRUGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTIPLATELET DRUGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ARRHYTHMIA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ARRHYTHMIA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY HYPERLIPIDAEMIA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY HYPERLIPIDAEMIA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY HYPERTENSION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ORAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY PRESCRIPTION-BASED DRUGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY PRESCRIPTION-BASED DRUGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 52. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 53. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 54. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 55. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 56. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 57. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 58. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 59. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 60. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 61. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 62. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 63. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 64. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 65. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 66. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 67. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 68. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 69. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 70. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 71. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 72. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 73. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 74. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 75. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 76. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 77. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 78. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 79. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 80. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 81. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 82. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 83. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 84. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 85. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 86. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 87. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 88. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 89. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 90. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 91. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 92. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 93. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 94. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 95. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 96. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 97. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 98. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 99. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 100. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 101. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 102. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 103. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 104. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 105. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 106. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 107. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 108. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 109. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 110. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 111. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 112. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 113. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 114. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 128. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 130. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 132. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 134. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 135. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 136. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 137. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 138. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 139. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 140. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 141. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 142. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 143. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 144. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 145. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 146. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 147. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 148. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 149. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 150. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 151. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 152. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 153. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 154. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 155. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 156. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 157. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 160. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 161. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 162. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 163. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 164. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 165. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 166. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 167. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 168. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 169. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 170. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 171. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 172. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 173. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 174. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 175. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 176. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 177. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 178. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 179. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 180. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 181. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 182. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 183. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 184. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 185. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 186. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 188. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 189. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 190. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 191. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 192. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 193. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 194. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 195. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 196. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 197. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 198. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 199. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 200. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 201. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 202. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 203. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 204. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 205. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 206. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 207. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 208. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 209. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 210. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 211. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 212. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 213. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 214. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 215. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 216. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 217. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 218. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 219. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 220. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 221. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 222. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 223. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 224. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 225. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 226. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 227. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 228. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 229. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 230. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 231. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 232. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 233. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 234. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 235. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 236. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 237. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 238. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 239. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 240. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 241. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 242. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 243. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 244. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 245. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 246. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 259. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 260. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 261. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 262. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 263. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 264. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 265. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 266. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 267. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 268. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 269. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 270. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 271. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 272. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 273. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 274. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 275. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 276. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 277. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 278. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 279. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 280. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 281. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 282. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 283. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 284. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 285. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 286. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 287. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 288. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 289. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 290. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 291. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 292. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 293. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 294. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 295. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 296. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 297. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 298. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 299. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 300. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 301. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 302. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 303. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 304. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 305. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 306. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 307. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 308. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 309. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 310. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 311. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 312. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 313. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 314. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 315. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 316. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 317. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 318. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 319. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 320. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 321. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 322. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 323. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 324. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 325. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 326. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 327. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 328. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 329. NETHERLANDS CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 330. NETHERLANDS CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 331. NETHERLANDS CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 332. NETHERLANDS CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 333. NETHERLANDS CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRA